Sal Patel, JD, partner at Schiff Hardin, LLP, explains how the Supreme Court's 2017 ruling in Sandoz v Amgen changed the biosimilars landscape.
How has last year’s Supreme Court ruling in Sandoz v Amgen changed the biosimilars landscape?
Well, it changes the biosimilar landscape in that now, biosimilar developers can go ahead and file declaratory judgment actions. They don’t need to participate in that long and tortuous patent dance that was required. I think it makes it a little bit easier for biosimilar developers.